O	0	7	Reduced	Reduce	VBN	B-NP
O	8	20	oncogenicity	oncogenicity	NN	I-NP
O	21	23	of	of	IN	B-PP
O	24	28	p190	p190	NN	B-NP
O	29	32	Bcr	Bcr	NN	I-NP
O	32	33	/	/	SYM	B-VP
O	33	36	Abl	Abl	NN	B-NP
O	37	38	F	F	NN	I-NP
O	38	39	-	-	HYPH	B-NP
O	39	44	actin	actin	NN	I-NP
O	44	45	-	-	HYPH	O
O	45	52	binding	bind	VBG	B-VP
O	53	59	domain	domain	NN	B-NP
O	60	67	mutants	mutant	NNS	I-NP
O	67	68	.	.	.	O

O	70	73	The	The	DT	B-NP
O	74	85	deregulated	deregulate	VBN	I-NP
O	86	89	Bcr	Bcr	NN	I-NP
O	89	90	/	/	SYM	I-NP
O	90	93	Abl	Abl	NN	I-NP
O	94	102	tyrosine	tyrosine	NN	I-NP
O	103	109	kinase	kinase	NN	I-NP
O	110	112	is	be	VBZ	B-VP
O	113	124	responsible	responsible	JJ	B-ADJP
O	125	128	for	for	IN	B-PP
O	129	132	the	the	DT	B-NP
O	133	144	development	development	NN	I-NP
O	145	147	of	of	IN	B-PP
O	148	160	Philadelphia	Philadelphia	NNP	B-NP
O	161	162	(	(	(	O
O	162	164	Ph	Ph	NN	B-NP
O	164	165	)	)	)	O
O	165	166	-	-	HYPH	B-NP
O	166	174	positive	positive	JJ	I-NP
B-Cancer	175	183	leukemia	leukemia	NN	I-NP
O	184	186	in	in	IN	B-PP
O	187	193	humans	human	NNS	B-NP
O	193	194	.	.	.	O

O	195	197	To	To	TO	B-VP
O	198	209	investigate	investigate	VB	I-VP
O	210	213	the	the	DT	B-NP
O	214	226	significance	significance	NN	I-NP
O	227	229	of	of	IN	B-PP
O	230	233	the	the	DT	B-NP
O	234	235	C	C	NN	I-NP
O	235	236	-	-	HYPH	B-NP
O	236	244	terminal	terminal	JJ	I-NP
O	245	248	Abl	Abl	NN	I-NP
O	249	254	actin	actin	NN	I-NP
O	254	255	-	-	HYPH	O
O	255	262	binding	bind	VBG	B-NP
O	263	269	domain	domain	NN	I-NP
O	270	276	within	within	IN	B-PP
O	277	280	Bcr	Bcr	NN	B-NP
O	280	281	/	/	SYM	B-NP
O	281	284	Abl	Abl	NN	I-NP
O	285	289	p190	p190	NN	I-NP
O	290	292	in	in	IN	B-PP
O	293	296	the	the	DT	B-NP
O	297	308	development	development	NN	I-NP
O	309	311	of	of	IN	B-PP
B-Cancer	312	320	leukemia	leukemia	NN	B-NP
O	320	321	/	/	SYM	B-NP
B-Cancer	321	329	lymphoma	lymphoma	NN	I-NP
O	330	332	in	in	FW	B-ADVP
O	333	337	vivo	vivo	FW	I-ADVP
O	337	338	,	,	,	O
O	339	345	mutant	mutant	JJ	B-NP
O	346	350	p190	p190	NN	I-NP
O	351	354	DNA	DNA	NN	I-NP
O	355	365	constructs	construct	NNS	I-NP
O	366	370	were	be	VBD	B-VP
O	371	375	used	use	VBN	I-VP
O	376	378	to	to	TO	B-VP
O	379	387	generate	generate	VB	I-VP
O	388	398	transgenic	transgenic	JJ	B-NP
O	399	403	mice	mouse	NNS	I-NP
O	403	404	.	.	.	O

O	405	410	Eight	Eight	CD	B-NP
O	411	418	founder	founder	NN	I-NP
O	419	422	and	and	CC	I-NP
O	423	430	progeny	progeny	NN	I-NP
O	431	435	mice	mouse	NNS	I-NP
O	436	438	of	of	IN	B-PP
O	439	440	5	5	CD	B-NP
O	441	450	different	different	JJ	I-NP
O	451	456	lines	line	NNS	I-NP
O	457	461	were	be	VBD	B-VP
O	462	471	monitored	monitor	VBN	I-VP
O	472	475	for	for	IN	B-PP
O	476	490	leukemogenesis	leukemogenesis	NN	B-NP
O	490	491	.	.	.	O

O	492	499	Latency	Latency	NN	B-NP
O	500	503	was	be	VBD	B-VP
O	504	512	markedly	markedly	RB	I-VP
O	513	522	increased	increase	VBN	I-VP
O	523	526	and	and	CC	O
O	527	537	occurrence	occurrence	NN	B-NP
O	538	547	decreased	decrease	VBD	B-VP
O	548	550	in	in	IN	B-PP
O	551	554	the	the	DT	B-NP
O	555	559	p190	p190	NN	I-NP
O	560	563	del	del	NN	I-NP
O	564	565	C	C	NN	I-NP
O	566	571	lines	line	NNS	I-NP
O	572	574	as	as	IN	B-PP
O	575	583	compared	compare	VBN	B-PP
O	584	588	with	with	IN	B-PP
O	589	599	nonmutated	nonmutated	JJ	B-NP
O	600	604	p190	p190	NN	I-NP
O	605	608	BCR	BCR	NN	I-NP
O	608	609	/	/	SYM	B-NP
O	609	612	ABL	ABL	NN	I-NP
O	613	624	transgenics	transgenic	NNS	I-NP
O	624	625	.	.	.	O

O	626	633	Western	Western	NN	B-NP
O	634	638	blot	blot	NN	I-NP
O	639	647	analysis	analysis	NN	I-NP
O	648	650	of	of	IN	B-PP
O	651	659	involved	involve	VBN	B-NP
B-Tissue	660	671	hematologic	hematologic	JJ	I-NP
I-Tissue	672	679	tissues	tissue	NNS	I-NP
O	680	682	of	of	IN	B-PP
O	683	686	the	the	DT	B-NP
O	687	691	p190	p190	NN	I-NP
O	692	695	del	del	NN	I-NP
O	696	697	C	C	NN	I-NP
O	698	709	transgenics	transgenic	NNS	I-NP
O	710	714	with	with	IN	B-PP
O	715	718	end	end	NN	B-NP
O	718	719	-	-	HYPH	I-NP
O	719	724	stage	stage	NN	I-NP
O	725	732	disease	disease	NN	I-NP
O	733	739	showed	show	VBD	B-VP
O	740	744	high	high	JJ	B-NP
O	744	745	-	-	HYPH	I-NP
O	745	750	level	level	NN	I-NP
O	751	761	expression	expression	NN	I-NP
O	762	764	of	of	IN	B-PP
O	765	768	the	the	DT	B-NP
O	769	778	transgene	transgene	NN	I-NP
O	779	782	and	and	CC	I-NP
O	783	791	tyrosine	tyrosine	NN	I-NP
O	792	807	phosphorylation	phosphorylation	NN	I-NP
O	808	810	of	of	IN	B-PP
O	811	814	Cbl	Cbl	NN	B-NP
O	815	818	and	and	CC	I-NP
O	819	823	Hef1	Hef1	NN	I-NP
O	823	824	/	/	SYM	B-NP
O	824	827	Cas	Ca	NNS	I-NP
O	827	828	,	,	,	O
O	829	837	proteins	protein	NNS	B-NP
O	838	848	previously	previously	RB	B-VP
O	849	854	shown	show	VBN	I-VP
O	855	857	to	to	TO	I-VP
O	858	860	be	be	VB	I-VP
O	861	869	affected	affect	VBN	I-VP
O	870	872	by	by	IN	B-PP
O	873	876	Bcr	Bcr	NN	B-NP
O	876	877	/	/	SYM	B-NP
O	877	880	Abl	Abl	NN	I-NP
O	880	881	.	.	.	O

O	882	887	These	These	DT	B-NP
O	888	895	results	result	NNS	I-NP
O	896	900	show	show	VBP	B-VP
O	901	905	that	that	IN	B-SBAR
O	906	909	the	the	DT	B-NP
O	910	915	actin	actin	NN	I-NP
O	915	916	-	-	HYPH	B-PP
O	916	923	binding	bind	VBG	B-NP
O	924	930	domain	domain	NN	I-NP
O	931	933	of	of	IN	B-PP
O	934	937	Abl	Abl	NN	B-NP
O	938	946	enhances	enhance	VBZ	B-VP
B-Cancer	947	955	leukemia	leukemia	NN	B-NP
O	956	967	development	development	NN	I-NP
O	968	971	but	but	CC	O
O	972	976	does	do	VBZ	B-VP
O	977	980	not	not	RB	I-VP
O	981	987	appear	appear	VB	I-VP
O	988	990	to	to	TO	I-VP
O	991	993	be	be	VB	I-VP
O	994	996	an	an	DT	B-NP
O	997	1005	absolute	absolute	JJ	I-NP
O	1006	1017	requirement	requirement	NN	I-NP
O	1018	1021	for	for	IN	B-PP
O	1022	1036	leukemogenesis	leukemogenesis	NN	B-NP
O	1036	1037	.	.	.	O

